February 10, 2017 4:16pm


The offering was discounted from $0.50 and was completed at an overnight -$0.10 discount for gross proceeds of $8 M. BSTG closed at $0.30.



The offering was priced at $0.40 per share of common stock with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of $0.40 per share.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as exclusive placement agent for the offering.


The Bottom Line: VERY UGLY but, it got done in a very BAD environment. The question will be … what will the company do to regain ANY value for shareholders in 2017; it will take a thorough review of the regulatory focus, the operational and scientific development and those associated with the company.

Biostage (BSTG) closed DOWN another -$0.206 to $0.30 after Thursday’s $0.50 (-$0.117) after Wednesday’s $0.62 (-$0.08), Tuesday’s $0.709 (-$0.0145), Monday’s $0.72 (+$0.04) and last Friday’s $0.68 (-$0.075).

The closing date of 2/15/17